[go: up one dir, main page]

CA2374051A1 - Liberation d'agents faiblement solubles - Google Patents

Liberation d'agents faiblement solubles Download PDF

Info

Publication number
CA2374051A1
CA2374051A1 CA002374051A CA2374051A CA2374051A1 CA 2374051 A1 CA2374051 A1 CA 2374051A1 CA 002374051 A CA002374051 A CA 002374051A CA 2374051 A CA2374051 A CA 2374051A CA 2374051 A1 CA2374051 A1 CA 2374051A1
Authority
CA
Canada
Prior art keywords
core
weight
pellet according
water
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002374051A
Other languages
English (en)
Inventor
Mark Alexander Livingstone
Charles Tokunbo Adesuyi
David Montieth
Gordon Findlay Dawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenes Drug Delivery Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2374051A1 publication Critical patent/CA2374051A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une pastille à libération contrôlée destinée à libérer un principe actif faiblement soluble présentant un noyau qui contient le principe actif (comme par exemple, la nifédipine, le glibenclamide, la griséofulvine, l'oxaprozine, l'ibuprofène, le diclofénac, la nabumétone etc.), un glycol polyéthylène et un excipient; le noyau présentant un enrobage à base de cellulose hydrosoluble et de polymère acrylique non hydrosoluble. En outre, un agent de désintégration est de préférence contenu dans le noyau.
CA002374051A 1999-05-19 2000-05-18 Liberation d'agents faiblement solubles Abandoned CA2374051A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9911546.1 1999-05-19
GBGB9911546.1A GB9911546D0 (en) 1999-05-19 1999-05-19 Release of poorly soluble agents
PCT/GB2000/001856 WO2000071095A2 (fr) 1999-05-19 2000-05-18 Liberation d'agents faiblement solubles

Publications (1)

Publication Number Publication Date
CA2374051A1 true CA2374051A1 (fr) 2000-11-30

Family

ID=10853685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002374051A Abandoned CA2374051A1 (fr) 1999-05-19 2000-05-18 Liberation d'agents faiblement solubles

Country Status (6)

Country Link
EP (1) EP1198228A2 (fr)
JP (1) JP2003500347A (fr)
AU (1) AU5082700A (fr)
CA (1) CA2374051A1 (fr)
GB (1) GB9911546D0 (fr)
WO (1) WO2000071095A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4926495B2 (ja) * 2006-02-22 2012-05-09 興和株式会社 イブプロフェン含有コーティング顆粒
WO2007096902A2 (fr) * 2006-02-23 2007-08-30 Lupin Limited Nouvelles formes de doses solides de griséofulvine à usage oral
EP2134327A1 (fr) * 2007-03-13 2009-12-23 Sandoz AG Compositions pharmaceutiques de médicaments faiblement solubles
CN111481527B (zh) * 2020-04-30 2022-05-06 福建太平洋制药有限公司 一种提高布洛芬缓释胶囊成品收率的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets

Also Published As

Publication number Publication date
AU5082700A (en) 2000-12-12
JP2003500347A (ja) 2003-01-07
EP1198228A2 (fr) 2002-04-24
GB9911546D0 (en) 1999-07-21
WO2000071095A2 (fr) 2000-11-30
WO2000071095A3 (fr) 2001-01-25

Similar Documents

Publication Publication Date Title
AU2021282393B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP4549442B2 (ja) ミルナシプランの持続性放出を伴うガレヌス製剤形態
AP1206A (en) Enteric coated pharmaceutical composition and method of manufacturing.
EP1258249B1 (fr) Preparations orales pour diabete
JP2011513204A5 (fr)
US20010024660A1 (en) Enteric coated pharmaceutical composition and method of manufacturing
JP2002523443A (ja) オメプラゾール製剤
NZ517554A (en) Oral pharmaceutical forms of administration of tramadol with a delayed action
CZ284924B6 (cs) Prostředek s řízeným uvolňováním, který obsahuje morfinovou sůl
US20020076438A1 (en) High drug load acid labile pharmaceutical composition
US7829122B2 (en) Microgranules based on active principle and method for making same
JPWO2001023000A1 (ja) 消化管下部溶解性コーティング製剤
KR100354054B1 (ko) 유효성분으로서딜티아젬을함유하는지속방출형마이크로그래뉼
JP4785000B2 (ja) コーティング方法
CA2374051A1 (fr) Liberation d'agents faiblement solubles
US20090136550A1 (en) Modified release formulations of diltiazem
JPWO2002034268A1 (ja) ５−アセチル−４，６−ジメチル−２−［２−［４−（２−メトキシフェニル）ピペラジニル］エチルアミノ］ピリミジン・三塩酸塩を有効成分として含有する徐放性製剤
CA2547586C (fr) Formulation pharmaceutique a liberation controlee
CZ118899A3 (cs) Kompozice s pozvolným uvolňováním léčiva, způsob přípravy této kompozice, způsob zlepšení profilu uvolňování léčiva a použití této kompozice
WO2009063021A1 (fr) Formes pharmaceutiques permettant la libération de composés actifs
MXPA00010963A (en) Enteric coated pharmaceutical composition and method of manufacturing
NZ718686B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued